Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by stock analysts at Chardan Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $14.00 target price on the stock. Chardan Capital's price objective suggests a potential upside of 122.93% from the company's previous close.
Separately, D. Boral Capital restated a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Tuesday, April 22nd.
View Our Latest Report on COYA
Coya Therapeutics Price Performance
NASDAQ COYA traded down $0.31 on Monday, hitting $6.28. 40,413 shares of the company's stock were exchanged, compared to its average volume of 72,733. The firm's 50-day moving average price is $6.17 and its two-hundred day moving average price is $6.39. Coya Therapeutics has a fifty-two week low of $4.65 and a fifty-two week high of $10.24. The firm has a market cap of $105.03 million, a price-to-earnings ratio of -9.66 and a beta of 0.49.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.10 million. On average, research analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Coya Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. AIGH Capital Management LLC grew its holdings in Coya Therapeutics by 85.0% during the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company's stock valued at $6,883,000 after buying an additional 551,725 shares during the last quarter. DME Capital Management LP grew its holdings in Coya Therapeutics by 29.2% during the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after buying an additional 372,414 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in Coya Therapeutics during the 4th quarter valued at $401,000. CM Management LLC grew its holdings in Coya Therapeutics by 11.1% during the 4th quarter. CM Management LLC now owns 160,000 shares of the company's stock valued at $917,000 after buying an additional 15,941 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Coya Therapeutics during the 4th quarter valued at $74,000. Institutional investors and hedge funds own 39.75% of the company's stock.
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Further Reading
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
